30-day morbidity and mortality in randomised trials comparing CEA and CAS in asymptomatic patients
| 30-day outcomes | Lexington34 | CREST-1*18 | ACT-135 | SPACE-233 | Mannheim36 | ||||||
| CEA n=42 | CAS n=43 | CEA n=587 | CAS n=364 | CEA n=364 | CAS n=1089 | CEA n=203 | CAS n=197 | BMT n=113 | CEA n=68 | CAS n=68 | |
| Death/stroke | 0% | 0% | 1.4% | 2.5% | 1.7% | 2.9% | 2.0% | 2.5% | 0.0% | 1.5% | 2.9% |
| Death/disabling stroke | 0% | 0% | 0.3% | 0.5% | 0.6% | 0.6% | |||||
*Only asymptomatic patients in CREST-1 were included.
ACT-1, Asymptomatic Carotid Trial 1; CAS, carotid artery stenting; CEA, carotid endarterectomy; SPACE, Stent-Protected Angioplasty versus Carotid Endarterectomy.